Literature DB >> 12973949

Clinical implication of the changes of cAMP, TXA2 and PGI2 in CSF of asphyxiated newborns.

Hanchu Liu1, Liwen Chang, Ye Chen, Shiwen Xia, Xiaohui Zhang.   

Abstract

To evaluate the changes of 3', 5'-cyclic adenosine monophosphate (cAMP), thromboxane A2(TXA2) and prostacyclin (PGI2) in cerebrospinal fluid (CSF) in the asphyxiated newborn and explore their roles in hypoxic-ischemic brain damage (HIBD). Thirty-six full term newborns were divided into 3 groups, including 12 with moderate-severe hypoxic-ischaemic encephalopathy (HIE), 13 with mild HIE, 11 without HIE (control group). The levels of cAMP, TXB2 (TXA2 metabolite) and 6-keto-PGF1 alpha (PGI2 metabolite) in CSF and plasma were measured 36-72 h after birth by RIA, and the concentrations were expressed as nM/L (cAMP), ng/L(TXB2 and 6-keto-PGF1 alpha). The infants were followed-up at 6 and 12 month of age and Mental Development Index (MDI) and Psychomotor Development Index (PDI) were measured using Bayley Scales of Infant Development (BSID). The CSF cAMP level in moderate-severe HIE group was 8.60 +/- 2.40, significantly lower than that of the mild HIE group (14.83 +/- 2.84) and the control group (24.43 +/- 2.39) (for both P < 0.01). The levels of TXB2 and 6-keto-PGF1 alpha in CFS in the moderate-severe HIE group (206.06 +/- 29.74, 168.47 +/- 23.02, respectively) were significantly higher than in the mild HIE group (83.37 +/- 28.57, 131.42 +/- 16.57, respectively, P < 0.01) and the control group (41.77 +/- 21.58, 86.23 +/- 13.05, respectively, P < 0.01). The level changes of cAMP, TXB2 and 6-keto-PGF1 alpha in plasma in all groups were similar to those in CSF, but no significant difference was found between mild HIE group and the control group (P > 0.05). The follow-up results showed that MDI and PDI of the moderate-severe HIE group were the lowest (84.79 +/- 13.34, 83.50 +/- 13.28, respectively), followed by mild HIE group (102.19 +/- 7.02, 99.94 +/- 9.08, respectively), with the control group being the highest (116.63 +/- 12.08, 116.69 +/- 10.87, respectively). Univariate analysis showed some significant difference (the moderate-severe HIE group vs. the mild HIE group or the control group, P < 0.01; the mild HIE group vs. the control group P < 0.05). The results suggested that the concentration of cAMP, TXA2 and T/K ratio in CSF after neonatal asphyxia might be sensitive markers in evaluating the severity of brain damage in early stage and predicting the future outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12973949     DOI: 10.1007/BF02859956

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  4 in total

1.  Arachidonic acid metabolites in CSF in hypoxic-ischaemic encephalopathy of newborn infants.

Authors:  J M Vilanova; J Figueras-Aloy; J Roselló; G Gómez; E Gelpí; R Jiménez
Journal:  Acta Paediatr       Date:  1998-05       Impact factor: 2.299

2.  Role of cyclic nucleotides in vasopressin-induced piglet pial artery dilation and opioid release.

Authors:  M I Rossberg; W M Armstead
Journal:  Pediatr Res       Date:  1997-04       Impact factor: 3.756

3.  Prognostic significance of cerebrospinal fluid cyclic adenosine monophosphate in neonatal asphyxia.

Authors:  M Pourcyrous; H S Bada; W Yang; H Parfenova; S P Wong; S B Korones; C W Leffler
Journal:  J Pediatr       Date:  1999-01       Impact factor: 4.406

4.  Eicosanoids in human ventricular cerebrospinal fluid following severe brain injury.

Authors:  J Y Westcott; R C Murphy; K Stenmark
Journal:  Prostaglandins       Date:  1987-12
  4 in total
  2 in total

1.  Milrinone attenuates thromboxane receptor-mediated hyperresponsiveness in hypoxic pulmonary arterial myocytes.

Authors:  K T Santhosh; O Elkhateeb; N Nolette; O Outbih; A J Halayko; S Dakshinamurti
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

Review 2.  Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn.

Authors:  Batoule H Majed; Raouf A Khalil
Journal:  Pharmacol Rev       Date:  2012-06-07       Impact factor: 25.468

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.